Sarcopenia symptoms are easy to mistake for ordinary ageing. That is most of the reason the condition goes unrecognised for years: nothing about it feels like an illness starting.
Key takeaways
- The first thing people notice is usually function rather than appearance: rising from a low chair takes effort, stairs need a handrail, and walking pace drops without a decision being made about it.
- Weakness is the leading symptom by design. EWGSOP2 elevated low muscle strength to the primary indicator of probable sarcopenia precisely because it shows up first and predicts outcomes better than muscle size does.
- The SARC-F screening questionnaire asks about five things: strength, walking, rising from a chair, climbing stairs and falls.
- Body weight is a poor symptom. Muscle can be lost while the number on the scale stays flat, which is why clinicians measure grip strength and gait speed instead.
- Rapid onset, wasting on one side only, numbness, unintentional weight loss or trouble swallowing are not typical of sarcopenia and point somewhere else. Those need assessment rather than reassurance.
What sarcopenia symptoms actually look like
The literature describes sarcopenia in terms of measurements. Patients describe it in terms of tasks that used to be automatic.
Difficulty rising from a seated position. Getting out of a low armchair, a car seat or a bath now requires a push from the arms or a second attempt. This is often the earliest thing people notice, because it loads the quadriceps and hip extensors, and it is why the chair stand test appears in every diagnostic algorithm.
Slower walking. Not limping and not painful, just slower. Family members often register it before the person does, usually as being left behind on a walk that used to be shared comfortably.
Stairs becoming a decision. Reaching for the handrail, taking one step at a time, pausing at a landing.
Weaker grip. Jars, taps, bottle tops, carrying shopping in one hand, a heavy door. Grip is a useful proxy for whole-body strength, which is why it is the measure clinicians reach for.
Falls and near-falls. Stumbles that used to be caught are no longer caught, because the corrective step needs power that is no longer there.
Loss of endurance and stamina in everyday activity. Fatigue after tasks that used to be unremarkable.
Visible change in muscle bulk. Thinner arms and legs, clothing fitting differently, rings and watch straps loosening. This tends to come later than the functional changes, and it can be almost invisible in someone carrying more body fat.
What screening actually asks
EWGSOP2 recommends the SARC-F questionnaire for case finding in clinical practice. It is a five-item, self-reported questionnaire, and the five items map directly onto the symptom list above: perceived strength, walking ability, rising from a chair, climbing stairs and experiences with falls.
Its limitation is worth knowing before you attach any weight to it. EWGSOP2 states plainly that SARC-F has low to moderate sensitivity and very high specificity for predicting low muscle strength, which means it will mostly detect severe cases. A reassuring score is not evidence that nothing is happening. The consensus recommends it as a way of introducing assessment into practice, not as a substitute for measurement.
What is not a sarcopenia symptom
This part matters as much as the list above, because attributing the wrong symptom to sarcopenia delays a diagnosis that needed attention.
Pain is not a feature. Muscle loss itself does not hurt. Painful weakness suggests an inflammatory muscle disease, a nerve problem or a joint problem, and it warrants investigation on its own terms.
Weight loss is not required. Someone can meet criteria for sarcopenia while their weight is stable or rising, because fat mass can replace what muscle mass has lost. Weight alone tells you almost nothing here.
Asymmetry is atypical. Sarcopenia is a generalised process. Wasting confined to one limb, one nerve distribution or one side of the body is a different problem, and our muscle atrophy guide covers what those patterns usually indicate.
Sudden onset is atypical for the chronic form. EWGSOP2 does recognise acute sarcopenia, lasting under six months and usually triggered by an acute illness or injury. But weakness that appears over days without an obvious precipitant is not something to explain away.
Numbness, tingling, twitching, difficulty swallowing, slurred speech, drooping eyelids or breathlessness are not sarcopenia symptoms. Any of them alongside weakness is a reason to be seen promptly.
Why the symptoms get missed
Three things conspire.
The onset is slow enough that people adapt without noticing they have adapted. Behaviour changes first: fewer stairs, shorter walks, the higher chair by preference. By the time the symptom is articulated, the adaptation has been running for a while.
The symptoms are also socially expected. "Slowing down" is treated as a normal part of ageing, so neither the patient nor the people around them treat it as reportable. And because muscle loss can be masked by unchanged body weight, routine measurements in a clinic can look entirely normal.
What happens when you report these symptoms
The EWGSOP2 pathway is Find, Assess, Confirm, Severity. In practice that means:
- Case finding. SARC-F or clinical suspicion based on what you have described.
- Assessment of strength. Grip strength with a dynamometer, or a timed five-repetition chair stand test. The published European thresholds are grip strength below 27 kg in men and below 16 kg in women, and more than 15 seconds for five chair rises.
- Confirmation of muscle quantity. DXA or bioelectrical impedance in ordinary clinical care.
- Severity. Physical performance measures, most commonly gait speed, with 0.8 m/s or less used as the threshold.
Alongside that, a clinician looks for causes other than ageing, since low strength can also come from depression, stroke, balance disorders and peripheral vascular disease. The sarcopenia definition page sets out the full criteria and the reasoning behind them.
What the symptoms predict
This is why the assessment is worth having. The 2019 Lancet seminar on sarcopenia describes it as a progressive and generalised skeletal muscle disorder associated with increased adverse outcomes including falls, functional decline, frailty and mortality.
That is the argument for reporting the symptoms early rather than accommodating them. What the evidence supports doing about it is covered on our sarcopenia treatment page.
Symptoms after a hospital stay
A specific pattern is worth flagging, because it is common and it is fast.
Eleven healthy adults averaging 67 years old spent 10 days on continuous bed rest, eating a diet that met the recommended protein allowance. Knee extensor strength fell 13.2%, stair-climbing power fell 14%, and maximal aerobic capacity fell 12%. Those were healthy volunteers. An older adult admitted with an acute illness has the same unloading plus the illness itself.
If someone comes out of hospital and cannot manage stairs or a chair the way they did going in, that is worth raising rather than waiting to see whether it settles.
The myostatin question
Readers arrive at this site asking whether myostatin explains the symptoms above and whether blocking it would relieve them.
Myostatin, or GDF-8, is a negative regulator of muscle mass, and the pathway has been an obvious therapeutic target since the 1997 Nature paper describing mice that lacked it. The trial record is examined on our myostatin and sarcopenia page. The relevant point for symptoms is that adding lean mass and relieving the functional complaints described here have turned out to be different achievements, and so far only the first has been reliably demonstrated.
Frequently asked questions
What is usually the first sign of sarcopenia?
Loss of strength, most often noticed as difficulty rising from a low chair or as needing a handrail on stairs. EWGSOP2 places low muscle strength first in its definition because it appears before visible loss of bulk and predicts outcomes better than muscle size does.
Does sarcopenia cause pain?
Muscle loss itself is not painful. Pain accompanying weakness points toward a different or additional problem, such as an inflammatory muscle disease, a nerve compression or joint disease, and should be assessed rather than attributed to sarcopenia.
Can you have sarcopenia at a normal body weight?
Yes. Muscle can be lost while fat mass increases, leaving body weight and body mass index unchanged. This is why the diagnostic criteria use grip strength, chair stand time, gait speed and direct measures of muscle quantity rather than weight.
Is the SARC-F questionnaire enough to rule sarcopenia out?
No. EWGSOP2 notes that SARC-F has low to moderate sensitivity and very high specificity, so it mainly picks up severe cases. It is a case-finding tool intended to prompt assessment, and a reassuring result does not replace measured grip strength or a chair stand test.
Which symptoms mean something other than sarcopenia?
Wasting on one side or in one limb, numbness or tingling, muscle twitching, unintentional weight loss, difficulty swallowing, slurred speech, drooping eyelids and breathlessness are not features of sarcopenia. Weakness that appears over days rather than months also needs a different explanation. All of these warrant prompt medical assessment.
How quickly do symptoms appear after illness or bed rest?
Quickly. In healthy adults averaging 67 years old, 10 days of continuous bed rest produced a 13.2% fall in knee extensor strength and a 14% fall in stair-climbing power, despite adequate protein intake. Functional decline after a hospital admission is common and is worth reporting rather than waiting out.
Sources
- Cruz-Jentoft AJ et al. Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2). Age Ageing 2019;48(1):16-31
- Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet 2019;393(10191):2636-2646
- Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc 2013;14(8):531-2
- Kortebein P et al. Functional impact of 10 days of bed rest in healthy older adults. J Gerontol A Biol Sci Med Sci 2008;63(10):1076-81
- Ardeljan AD, Hurezeanu R. Sarcopenia. StatPearls, NCBI Bookshelf
- McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83-90
This article is for educational purposes only and is not medical advice. It describes symptoms reported in the clinical literature and does not diagnose any condition. The thresholds mentioned are research and clinical criteria, not a self-assessment tool. If you or someone you care for has weakness, falls or unexplained muscle loss, speak with a qualified healthcare professional.